Full Press Release Details
Pharmaceuticals to Present at the
UBS Global Health Care Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--May 19, 2015--Aurinia
Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its
Chief Executive Officer, Stephen W. Zaruby, will present a corporate
overview of the company at the 2015 UBS Global Health Care Conference,
taking place May 18th - 20th, 2015 in New
York at the Sheraton New York Times Square Hotel.
Aurinia Presentation Details
Time: 11:30 a.m. Eastern
Sheraton Time Square Hotel - Riverside Room
Aurinia is a clinical stage pharmaceutical company focused on the global
nephrology market. It is currently enrolling patients in its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis ("LN"). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best in class calcineurin
inhibitor ("CNI") with extensive clinical data in over 2,000 patients in
other indications. Voclosporin is made by a modification of a single
amino acid of the cyclosporine molecule (a CNI approved for use in
transplant patients since 1983). This modification results in a more
predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency vs. cyclosporine, an altered metabolic profile, and
potential for flat dosing.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals Inc.
Zaruby, 206-755-7520
President & Chief Executive Officer
Michael R. Martin, 250-708-4272